Completed PHASE1 INTERVENTIONAL 7-arm NCT03757559

A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

A Single-dose, Nested-randomized, Double-blind, Double-dummy, Placebo- and Active-controlled Crossover Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

Sponsor: Tris Pharma, Inc.

Conditions Abuse, Drug

Interventions Cebranopadol 100 micrograms Cebranopadol 400 micrograms Hydromorphone hydrochloride 4 milligrams Placebo matching cebranopadol Placebo matching hydromorphone

Updated 6 times since 2018 Last updated: Jul 13, 2021 Started: Apr 15, 2013 Primary completion: Mar 8, 2014 Completion: Mar 8, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03757559, this PHASE1 trial focuses on Abuse, Drug and remains completed. Sponsored by Tris Pharma, Inc., it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Sep 2021 [monthly]

Completed PHASE1
Jan 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Dec 2018 — Jan 2019 [monthly]

Completed PHASE1

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tris Pharma, Inc.

Data source: Tris Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada